TNFRSF8 and Hodgkins lymphoma: The AFM13 BiKE is currently being tested in the clinic in combination with non-engineered allogeneic NK cells and AFM13-pretreated CB-NK cells (modified NK cells) for CD30+ Hodgkin lymphoma and non-Hodgkin lymphoma [clinicaltrials.gov ID: NCT05883449 and NCT04074746].